Fertility and assisted reproduction
A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count
Article first published online: 29 MAR 2010
© 2010 The Authors Journal compilation © RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 117, Issue 7, pages 853–862, June 2010
How to Cite
Jayaprakasan, K., Hopkisson, J., Campbell, B., Johnson, I., Thornton, J. and Raine-Fenning, N. (2010), A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. BJOG: An International Journal of Obstetrics & Gynaecology, 117: 853–862. doi: 10.1111/j.1471-0528.2010.02545.x
- Issue published online: 10 MAY 2010
- Article first published online: 29 MAR 2010
- Accepted 10 February 2010. Published Online 29 March 2010.
- Antral follicle count;
- IVF/ICSI outcome;
- ovarian response;
- predicted normal responders;
- randomised controlled trial;
- recombinant gonadotrophin
Please cite this paper as: Jayaprakasan K, Hopkisson J, Campbell B, Johnson I, Thornton J, Raine-Fenning N. A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. BJOG 2010;117:853–862.
Objective To test the hypothesis that among women predicted to have a normal ovarian response, ovarian stimulation using 300 IU follicle-stimulating hormone (FSH) results in the retrieval of more mature oocytes than 225 IU during in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) treatment.
Design Prospective randomised controlled study.
Setting University-based assisted conception unit.
Population A cohort of 131 women predicted to have a normal ovarian response to gonadotrophin stimulation, based on antral follicle count.
Methods Subjects undergoing their first cycle of IVF/ICSI were randomised to receive a fixed daily dose of 300 (experimental arm) or 225 IU (control arm) of recombinant FSH (Gonal-F).
Main outcome measures Number of mature oocytes retrieved and live birth rates.
Results The number (mean ± standard deviation) of mature oocytes retrieved (8.2 ± 5.0 versus 9.0 ± 4.8, for 300 and 225 IU, respectively; P = 0.34) was similar in each group. There were no differences between the 300- and 225 IU arms in live birth rates (31 versus 41%, respectively; P = 0.25), cycle cancellations resulting from insufficient ovarian response (0 versus 6.1%, respectively; P = 0.12), and prevalence of moderate (3.1 versus 3.0, respectively; P = 1.0) and severe (0 versus 1.5%, respectively; P = 1.0) ovarian hyperstimulation syndrome.
Conclusions The use of a higher daily dose of 300 IU of recombinant FSH for ovarian stimulation does not improve the number of mature oocytes retrieved, or live birth rates, among women with a predicted normal response during conventional IVF/ICSI.